Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00616733 · ClinicalTrials.gov registry record · Phase 1
12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients
A Phase 1 study of Multiple Sclerosis, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 5
- Study locations
NCT00616733: Completed Phase 1 study of Multiple Sclerosis, sponsored by Daiichi Sankyo.
NCT00616733 is a Phase 1 study of Multiple Sclerosis that has completed, run by Daiichi Sankyo. The registered enrollment target is 25 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00616733, a Phase 1 study of Multiple Sclerosis, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a 12-week study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of oral CS-0777 in patients with Multiple Sclerosis.
Conditions Studied
Interventions
- DRUG CS-0777 tablets
Study Locations (5)
Colorado
- - Denver
Florida
- - Port Orange
Kansas
- - Lenexa
Montana
- - Billings
Pennsylvania
- - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-03 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
What the finished NCT00616733 record still lists
NCT00616733 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which CS-0777 tablets is the first listed.
NCT00616733 lists 5 locations in 5 states (Colorado, Florida, Kansas).
Frequently Asked Questions
What is clinical trial NCT00616733 about?
NCT00616733 is a clinical study titled "12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients". This is a 12-week study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of oral CS-0777 in patients with Multiple Sclerosis.
What is the current status of trial NCT00616733?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2008-03. Estimated completion is 2010-09.
What conditions does trial NCT00616733 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT00616733?
The interventions under investigation include: CS-0777 tablets (DRUG).
Who is sponsoring clinical trial NCT00616733?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00616733 being conducted?
This trial has 5 study locations across Colorado, Florida, Kansas, Montana, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00616733's enrollment target sits among peer trials
25 243rd of 315 higher than 71 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
RECRUITING · Phase 1
-
Molecular Imaging of NET Using [C-11]MRB-PET in MS
RECRUITING · Phase 1
-
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia